Moderna Stock Is Soaring on Cancer Vaccine Buzz. Is It Too Late to Get In?

Moderna has surged more than 650% this year on cancer vaccine excitement, but analyst targets sit far below the current share price. Before you chase the rally, there are some uncomfortable numbers you need to see first.